Is His Elevated PSA Due to Cancer?

 

The Proof is in the PSA Protein Structure

 
 

By singling out PSA proteins that came from cancer cells, the IsoPSA test can help identify men who would not benefit from a biopsy

 
Cancerous and Normal Cell side by side, both showing how each emit normal or modified PSA proteins (cancerous)
 
IsoPSA_Landing-Page.jpg


How is IsoPSA Different?

Prostate cancer can cause PSA levels to increase, but so can benign factors such as enlargement of the prostate, infections, sexual activity, even undergoing a prostate exam.

Assessing the structure of PSA is more specific and a direct measure of cancer which can help determine if it originated from a cancer cell.

 
Two test tubes filled with a reagent - one on the right being dosed with patient blood sample, showing both normal and modified proteins) - on the right, the solution has separated the normal and modified proteins into layers which indicate a result
 
gradient-1-green.jpg
 

IsoPSA is a simpler, more accurate way to assess risk of having clinically significant prostate cancer

IsoPSA is a blood test for men with elevated total PSA ≥ 4ng/mL that identifies structural differences in PSA proteins that are expressed by cancer.

IsoPSA can clarify prostate cancer risk, enabling better biopsy decisions for patients who are either biopsy naïve or who have had prior negative biopsy.

white-background.jpg

How is IsoPSA Better?

 
 

If you are a Healthcare Provider interested in offering IsoPSA testing to your patients, contact us:

burst-gradient.jpg

CONTRAINDICATIONS:

IsoPSA is not indicated for men under 50 years of age, men who have had a recent (<72 hours) prostate manipulation, including DRE; recent (<2 weeks) UTI and/or prostatitis; recent (<30 days) prostate surgery, urinary catheterization, prostate infarction, or endoscopic evaluation; or diagnosis of prostate cancer or other urinary tract malignancy.

If you are a Healthcare Provider interested in offering IsoPSA testing to your patients, contact us

 

1 Klein, et al., Urol Oncol. 2022 Sep;40(9):408.e9-408.e18.
2 Benidir et al., Urology. 2023 Jun;176:115-120.
3 Scovell et al., Urology. 2023 May;175:132-136.
4 Scovell, et al., Urol Pract. 2022 Mar;9(2):173-180
* CGS LCD L39284

bod.jpg